James Boylan snags $300M to hunt for biotech deals after leaving SVB
After three decades in healthcare investment banking, culminating in serving as SVB president, James Boylan is headed to the other side of the industry.
Specifically, he’s the new CEO of Patient Square Capital’s biotech investment company Enavate Sciences, which launches Monday with $300 million to go after “middle innings” private and public biotechs.
“The opportunity to really sit shoulder to shoulder with people that used to be my clients and now will be my partners was so exciting it pulled me out of retirement,” Boylan told Endpoints News after taking a year off to be with family.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.